MCRB Seres Therapeutics Inc.

3.68
-0.03  -1%
Previous Close 3.71
Open 3.72
Price To Book -8
Market Cap 257,641,775
Shares 70,011,352
Volume 78,632
Short Ratio
Av. Daily Volume 223,799
Stock charts supplied by TradingView

NewsSee all news

  1. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  2. Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET. A live audio webcast of the presentation

  3. Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update

    – Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 – – Debt facility secured, providing up to $50 million in additional capital; Corporate

  4. Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general

  5. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due mid-2020.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 2b data due 2H 2020.
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b data due 2H 2020.
SER-401
Melanoma

Latest News

  1. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  2. Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET. A live audio webcast of the presentation

  3. Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update

    – Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 – – Debt facility secured, providing up to $50 million in additional capital; Corporate

  4. Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general

  5. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  6. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic

  7. 4BIO Capital raises $50 million in first close of new advanced therapies fund

    Press Release 4BIO Capital raises $50 million in first close of new advanced therapies fund             4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close 9 September 2019